A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae

Vaccine

Volumn 29, Issue 33, 2011, Pages 5495-5501

  Denoël, Philippe ^a   Philipp, Mario T ^b   Doyle, Lara ^b   Martin, Dale ^b   Carletti, Georges ^a   Poolman, Jan T ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

PhtD; Pneumolysin; Pneumonia; Rhesus macaque; Streptococcus pneumoniae; Vaccine

Indexed keywords

3 O DESACYL 4' MONOPHOSPHORYL LIPID A; BACTERIAL PROTEIN; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1BETA; INTERLEUKIN 6; PNEUMOCOCCAL HISTIDINE TRIAD PROTEIN D; PNEUMOCOCCAL HISTIDINE TRIAD PROTEIN D ANTIBODY; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; PNEUMOLYSIN ANTIBODY; PROTEIN ANTIBODY; QS 21; TOXIN ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG FORMULATION; IMMUNIZATION; LUNG LAVAGE; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SEROLOGY; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL LOAD; BACTERIAL PROTEINS; DISEASE MODELS, ANIMAL; HYDROLASES; IMMUNIZATION, SECONDARY; LUNG; MACACA MULATTA; MALE; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PRIMATE DISEASES; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS; SURVIVAL ANALYSIS; VACCINATION; VACCINES, SUBUNIT;

EID: 79960342392     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.051     Document Type: Article

References (38)

1. Hausdorff W.P., Feikin D.R., Klugman K.P. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005, 5(2):83-93.
2. McCullers J.A., Tuomanen E.I. Molecular pathogenesis of pneumococcal pneumonia. Front Biosci 2001, 6:D877-D889.
3. Lynch J.P., Zhanel G.G. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy. Semin Respir Crit Care Med 2005, 26(6):575-616.
4. Bridy-Pappas A.E., Margolis M.B., Center K.J., Isaacman D.J. Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention. Pharmacotherapy 2005, 25(9):1193-1212.
5. Dagan R., Käyhty H., Wuorimaa T., Yaich M., Bailleux F., Zamir O., et al. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants. Pediatr Infect Dis J 2004, 23(2):91-98.
6. Fedson D.C., Musher D.M. Pneumococcal polysaccharide vaccines. Vaccines 2004, 529-588. Elsevier, Inc, Philadelphia, PA. S.A. Plotkin, W.A. Orenstein (Eds.).
7. Mbelle N., Huebner R.E., Wasas A.D., Kimura A., Chang I., Klugman K.P. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999, 180(4):1171-1176.
8. Smart L.E., Dougall A.J., Girdwood R.W.A. New 23-valent pneumococcal vaccine in relation to pneumococcal serotypes in systemic and non-systemic disease. J Infect 1987, 14(3):209-215.
9. Kanclerski K., Möllby R. Production and purification of Streptococcus pneumoniae hemolysin (pneumolysin). J Clin Microbiol 1987, 25(2):222-225.
10. Paton J.C., Lock R.A., Hansman D.J. Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae. Infect Immun 1983, 40(2):548-552.
11. Marriott H.M., Mitchell T.J., Dockrell D.H. Pneumolysin: a double-edged sword during the host-pathogen interaction. Curr Mol Med 2008, 8(6):497-509.
12. Francis J.P., Richmond P.C., Pomat W.S., Michael A., Keno H., Phuanukoonnon S., et al. Maternal antibodies to pneumolysin but not to pneumococcal surface protein A delay early pneumococcal carriage in high-risk Papua New Guinean infants. Clin Vaccine Immunol 2009, 16(11):1633-1638.
13. Huo Z., Spencer O., Miles J., Johnson J., Holliman R., Sheldon J., et al. Antibody response to pneumolysin and to pneumococcal capsular polysaccharide in healthy individuals and Streptococcus pneumoniae infected patients. Vaccine 2004, 22(9-10):1157-1161.
14. Amdahl B.M., Rubins J.B., Daley C.L., Gilks C.F., Hopewell P.C., Janoff E.N. Impaired natural immunity to pneumolysin during human immunodeficiency virus infection in the United States and Africa. Am J Respir Crit Care Med 1995, 152(6):2000-2004.
15. Alexander J.E., Lock R.A., Peeters C.C.A.M., Poolman J.T., Andrew P.W., Mitchell T.J., et al. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun 1994, 62(12):5683-5688.
16. Kirkham L.-A.S., Kerr A.R., Douce G.R., Paterson G.K., Dilts D.A., Liu D.-F., et al. Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines. Infect Immun 2006, 74(1):586-593.
17. Paton J.C., Lock R.A., Lee C.-J., Li J.P., Berry A.M., Mitchell T.J., et al. Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide. Infect Immun 1991, 59(7):2297-2304.
18. Hamel J., Charland N., Pineau I., Ouellet C., Rioux S., Martin D., et al. Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins. Infect Immun 2004, 72(5):2659-2670.
19. Rioux S., Neyt C., Di Paolo E., Turpin L., Charland N., Labbé S., et al. Transcriptional regulation, occurrence and putative role of the Pht family of Streptococcus pneumoniae. Microbiology 2011, 157(2):335-348.
20. Zhang Y., Masi A.W., Barniak V., Mountzouros K., Hostetter M.K., Green B.A. Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae, protects mice against intranasal pneumococcal challenge. Infect Immun 2001, 69(6):3827-3836.
21. Beghetto E., Gargano N., Ricci S., Garufi G., Peppoloni S., Montagnani F., et al. Discovery of novel Streptococcus pneumoniae antigens by screening a whole-genomeλ-display library. FEMS Microbiol Lett 2006, 262(1):14-21.
22. Hava D.L., Camilli A. Large-scale identification of serotype 4 Streptococcus pneumoniae virulence factors. Mol Microbiol 2002, 45(5):1389-1405.
23. Loisel E., Jacquamet L., Serre L., Bauvois C., Ferrer J.L., Vernet T., et al. AdcAII, a new pneumococcal Zn-binding protein homologous with ABC transporters: biochemical and structural analysis. J Mol Biol 2008, 381(3):594-606.
24. Riboldi-Tunnicliffe A., Isaacs N.W., itchell M.T.J. 1.2Å crystal structure of the S. pneumoniae PhtA histidine triad domain a novel zinc binding fold. FEBS Lett 2005, 579(24):5353-5360.
25. Adamou J.E., Heinrichs J.H., Erwin A.L., Walsh W., Gayle T., Dormitzer M., et al. Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun 2001, 69(2):949-958.
26. Godfroid F., Hermand P., Verlant V., Denoël P., Poolman J.T. Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect Immun 2011, 79(1):238-245.
27. Ogunniyi A.D., Grabowicz M., Briles D.E., Cook J., Paton J.C. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun 2007, 75(1):350-357.
28. Wizemann T.M., Heinrichs J.H., Adamou J.E., Erwin A.L., Kunsch C., Choi G.H., et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun 2001, 69(3):1593-1598.
29. Philipp M.T., Purcell J.E., Martin D.S., Buck W.R., Plauché G.B., Ribka E.P., et al. Experimental infection of rhesus macaques with Streptococcus pneumoniae: a possible model for vaccine assessment. J Med Primatol 2006, 35(3):113-122.
30. Sorensen R.U., Leiva L.E., Javier F.C., Sacerdote D.M., Bradford N., Butler B., et al. Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol 1998, 102(2):215-221.
31. Garçon N., Chomez P., Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6(5):723-739.
32. Abel K. The rhesus macaque pediatric SIV infection model: a valuable tool in understanding infant HIV pathogenesis and for designing pediatric HIV prevention strategies. Curr HIV Res 2009, 7(1):2-11.
33. Baroncelli S., Negri D.R.M., Michelini Z., Cara A. Macaca mulatta, fascicularis and nemestrina in AIDS vaccine development. Expert Rev Vaccines 2008, 7(9):1419-1434.
34. Gardner M.B., Luciw P.A. Macaque models of human infectious disease. ILAR J 2008, 49(2):220-255.
35. McMurray D.N. A nonhuman primate model for preclinical testing of new tuberculosis vaccines. Clin Infect Dis 2000, 30(Suppl. 3):S210-S212.
36. Staprans S.I., Feinberg M.B. The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines. Expert Rev Vaccines 2004, 3(Suppl. 4):S5-S32.
37. Klugman K.P., Cutts F., Adegbola R.A., Black S., Madhi S.A., O'Brien K.L., et al. Meta-analysis of the efficacy of conjugate vaccines against invasive pneumococcal disease. Pneumococcal vaccines: the impact of conjugate vaccine 2008, 317-326. ASM Press, Washington, DC. G.R. Siber, K.P. Klugman, P.H. Makela (Eds.).
38. Shapiro E.D., Berg A.T., Austrian R., Schroeder D., Parcells V., Margolis A., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991, 325(21):1453-1460.